Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 1, 2002, Pages 57-68

  Lopes De Menezes, Daniel E ^a,b,c   Mayer, Lawrence D ^a,b,c  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antisense; Bcl 2; Breast cancer; Doxorubicin; Pharmacokinetics

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; OBLIMERSEN; PROTEIN BCL 2; TRITIUM; ANTHRACYCLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; ISOTOPE LABELING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SCINTILLATION COUNTING; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; BREAST CANCER; COMPARATIVE STUDY; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG UPTAKE; HEART; KIDNEY; KINETICS; LUNG; MUSCLE; SCID MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PROTEINS; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; FEMALE; GENES, BCL-2; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BINDING; THIONUCLEOTIDES; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036137646     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0385-3     Document Type: Article

References (36)

1. Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
2. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topo-isomerase II-induced DNA strand breaks and their repair
3. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
4. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis
5. Antisense oligonucleotides suppress Bcell lymphoma growth in a SCID-hu mouse model
6. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
7. Inhibition of Rous sarcoma virus replication and cell transformation by a oligodeoxynucleotide
8. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides
9. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to Bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
10. Mechanisms of apoptosis avoidance in cancer
11. Apoptosis: An overview of the process and its relevance in disease
12. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
13. Synergistic cytotoxicity of Bcl-2 antisense oligodeoxynucleotide and etoposide, doxorubicin and cisplatin in small-cell lung cancer cell lines
14. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins
15. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model
16. Therapeutic and pharmacokinetic properties of free and liposomal doxorubicin combined with Bcl-2 antisense oligonucleotide treatment
17. Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low dose cyclophosphamide
18. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
19. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
20. MDA435/LCC6 and MDA435/LCC6MDRl: Ascites models of human breast cancer
21. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice
22. Liposomal doxorubicin circumvents PSC833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors
23. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
24. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
25. Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity
26. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells
27. Identification and characterization of second-generation antisense oligonucleotides
28. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
29. A phase I trial of an antisense oligonucleotide to Bcl-2 (G3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC)
30. A phase I study of Bcl-2 antisense G3139 (Genta) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
31. A phase I trial of G3139 (Genta Inc.) a Bcl-2 antisense drug, by continuous infusion (CI) as a single agent and with weekly Taxol (T)
32. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice
33. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate
34. High performance liquid chromatographic analysis of phosphorothioates in biological fluids
35. Plasma and serum protein binding of antisense oligodeoxynucleotide phosphorothioates in experimental animals and humans
36. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution